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Resident pools of somatic stem cells in many organs are responsible for tissue maintenance and 
repair. The goal of regenerative medicine is to exploit these cells either by transplanting them from 
an exogenous source or by activating endogenous stem cells pharmacologically. For diseases 
caused by mutations in a single gene, the therapeutic goal is tissue replacement using stem cells 
engineered to correct the genetic defect. However, a number of technical hurdles must be over-
come before therapies based on pluripotent human stem cells can enter the clinic.Our aging human population is increas-
ingly burdened by degenerative dis-
eases that are largely treated by sur-
gery and drugs designed to mitigate 
symptoms. Given their role in maintain-
ing and replenishing tissues, stem cells 
represent a potential means of restor-
ing tissue function and thereby treating 
the root cause of degenerative disease. 
Gene therapy for genetic diseases might 
also prove feasible when coupled to ex 
vivo repair of the patient’s stem cells 
prior to autologous transplantation. 
The pharmaceutical industry is adept 
at medicinal chemistry and the manu-
facture of protein therapeutics with the 
same degree of precision as the manu-
facture of small molecules. However, 
industry has yet to master the produc-
tion of pharmaceutical grade cells, and 
a business model whereby cells can be 
manufactured as products that can be 
purchased “off-the-shelf” has proven 
elusive (see Analysis by A. Parson in this 
issue of Cell). This raises central ques-
tions for the future of cell-based thera-
pies, especially those based on stem 
cells. Must cell therapies always be cus-
tomized for specific patients and thus 
remain a labor-intensive, individualized 
form of medical treatment? Or can cells 
be produced in bulk from master stocks 
of cells and be delivered directly from 
cell banks to patients in response to a 
physician’s prescription? What are the 
prospects for delivering drugs that aug-544 Cell 132, February 22, 2008 ©2008 Elsement endogenous stem cell pools? The 
answers to these questions will dictate 
the manner in which stem cells impact 
regenerative medicine.
Stem Cells as Therapy
Stem cells can be used to restore tissue 
function either as integrated participants 
in the target tissue or as vehicles that 
deliver complex signals to a target tissue 
without actually integrating into the tissue 
itself. Transplantation of hematopoietic 
stem cells (HSCs) is the gold standard 
for restoring tissue function by engraft-
ment of the stem cells directly into target 
tissue. In contrast, mesenchymal stem/
progenitor cells (MSCs) appear to work 
by the second mechanism to improve 
damaged heart tissue.
MSCs offer a strategy for using stem 
cells as a platform to deliver drug-like 
effects as they do not appear to be 
incorporated into tissues in settings 
such as ischemic cardiac injury. This 
lack of incorporation and the complex-
ity of measuring improved cardiac tis-
sue performance have engendered 
controversy about their use, yet the 
number of studies that indicate at least 
a short-term beneficial effect is hard to 
dismiss. MSCs appear to provide some 
paracrine trophic effect that may in part 
be mediated by modulators of Wnt sig-
naling such as secreted frizzled related 
protein-2 (Mirotsou et al., 2007). Stud-
ies of other tissue injury models such as vier Inc.graft-versus-host disease or bleomycin-
induced mouse lung injury also note 
amelioration of damage with infusions 
of MSCs, which they propose is due to 
anti-inflammatory effects (in the latter 
case through the release of IL-1 receptor 
antagonist; Ortiz et al., 2007). Although 
the immunologic or tissue trophic effects 
of MSCs are being elucidated, their real 
therapeutic potential remains unclear.
Driving Traffic in the Right Direction
If somatic stem cells are to serve as fac-
tor delivery vehicles or be incorporated 
into tissue, we need to know how they 
traffic to their targeted sites. All somatic 
stem cells migrate during development. 
Notably and of great therapeutic conse-
quence, HSCs continue to migrate in the 
mature mammal and therefore hematol-
ogists/oncologists can collect HSCs for 
transplantation by pheresis. However, 
large numbers of HSCs must still be 
collected because we do not know the 
most efficient way to deliver them to their 
sites of action. There is ample evidence 
that molecules such as α4- and α6β1-
integrins, PSGL-1, and E- and L-selectin 
ligands participate in the interaction of 
HSCs with endothelium (see Review by 
D.J. Laird et al. in this issue). Also, the 
CXC chemokine, stromal derived factor-1 
(SDF-1) or CXCL12, has been implicated 
in transmigration of HSCs to the bone 
marrow during development. However, 
SDF-1 and its receptor CXCR4 are not 
essential for bone marrow engraftment, 
suggesting that there is much to learn 
about the localization and engraftment 
of HSCs even though they are the best 
understood and clinically applied of all 
stem cell types.
Localization is even murkier with other 
stem cell types such as MSCs. Report-
edly, MSCs have been isolated from 
the circulation and, along with other tis-
sue stem cells, are believed to migrate 
to sites of injury (Palumbo et al., 2007; 
Wu et al., 2003). MSC migration appears 
to depend on molecules involved in 
immune cell localization such as the CC 
chemokine MCP-3 (Schenk et al., 2007) 
and β1 integrins (Ip et al., 2007). Whether 
SDF-1 or CXCR4 participate in local-
izing MSCs is controversial. A deeper 
investigation into homing has led to a 
new strategy for applying MSCs thera-
peutically. Ex vivo modification of the 
glycans on CD44, which is expressed 
by MSCs, modulates their interaction 
with receptors known to be expressed 
by the bone marrow microvasculature, 
dramatically increasing the efficiency of 
MSC delivery to bone (Sackstein et al., 
2008). Alternative strategies that target 
the site of desired localization are also 
being tested in the hopes of enriching the 
bed into which stem cells are recruited. 
Protease-resistant chemokines tethered 
to self-assembling peptides injected into 
a desired site of recruitment in the dam-
aged heart led to improvements not only 
in cell localization but also functional 
outcomes (Segers et al., 2007).
Stem Cells and Tissue Engineering
HSCs face the lowest hurdles for stem 
cell delivery because the liquid nature of 
hematopoiesis permits ready engage-
ment of the bone marrow. Clearly, there 
are very different requirements for the 
replacement of cardiac or neural tis-
sue. Replaying morphogenic programs 
to drive complex tissue relationships is 
a daunting prospect, casting doubt on 
these efforts. Recent evidence, however, 
suggests that recapitulating tissue struc-
ture may be possible. For example, vas-
cular cells derived from human embry-
onic stem cells (ESCs) can self-assemble 
into blood-carrying conduits in vivo and 
spontaneously enact anastamoses with 
the host vasculature (Levenberg et al., 
2002). Thus, there may be some degree 
of intrinsic morphogenic capability that 
will assist efforts to use cell replacement therapy or to create tissue constructs. 
This capability may be assisted by engi-
neered scaffolds. For example, cardio-
myocytes assemble into functional units 
that coordinate synchronous impulse 
propagation on biocompatible thin 
films in vitro and can be shaped into 3D 
structures (Feinberg et al., 2007). Also, 
matrices can be generated with graded 
concentrations of signaling and tether-
ing molecules that enable heterologous 
cells to assemble in an organized man-
ner. Combining cell-intrinsic morpho-
genic properties and engineered scaf-
folds to assist them offers the potential 
for more complex tissue reconstruction 
in the future. However, we need to bet-
ter understand organ morphogenesis to 
fully exploit this possibility. The interface 
of developmental and stem cell biology 
with tissue engineering ultimately prom-
ises to transform regenerative medicine.
In Situ Stem Cells as Targets for 
Therapy
Cell transplantation is but one of several 
ways in which somatic stem cells may 
contribute clinically. With the burgeon-
ing awareness of immature cell popu-
lations in many tissues that participate 
in maintenance and, under particular 
conditions, also repair damaged tissue, 
activating endogenous stem cells in situ 
has broad applications. The key is to 
identify which signals guide the behavior 
of these cells and to determine whether 
those signals can be pharmacologically 
modulated to induce a more vigorous 
reparative response. This requires a 
deeper understanding of the stem cell 
microenvironment or niche (see Review 
by S.J. Morrison and A.C. Spradling in 
this issue). Defining the components of 
that niche and how the niche translates 
tissue state into stem cell behavior will 
provide a rational basis for developing 
drugs to target endogenous stem cells.
One such example is the recognition 
that osteoblasts—a type of mesenchy-
mal cell in the bone marrow niche—
regulate the number of HSCs. However, 
the molecules involved, the requirement 
for physical interaction, and whether all 
or just a subset of osteoblasts partici-
pate remain to be determined (Calvi et 
al., 2003; Kiel et al., 2005; Zhang et al., 
2003). But what has been shown is that 
activation of the parathyroid receptor on Cell 132the osteoblast can change HSC behav-
ior resulting in increased stem cell num-
bers, enhanced tolerance to cytotoxic 
injury, and improved engraftment effi-
ciency in animal models (Adams et al., 
2007). These studies have now entered 
the clinical arena to determine whether 
parathyroid hormone can improve the 
outcome of patients receiving umbilical 
cord blood transplants.
Direct pharmacologic targeting of 
stem cells in vivo has some experimen-
tal support. For example, prostaglandin 
E2 was shown to increase zebrafish and 
mouse HSCs and improve the outcome 
of mouse bone marrow transplanta-
tion (North et al., 2007). Also, protea-
some inhibitors were shown to prompt 
increased MSC production of osteo-
blasts, in part by upregulating the tran-
scription factor Runx-2 (Mukherjee et al., 
2008). This strategy has been applied 
to a mouse model of osteoporosis to 
improve bone density.
The potential for modifying stem cells 
in situ is best illustrated by a bold set of 
experiments pairing animals of differ-
ent ages by surgical connection of their 
circulatory systems. This parabiosis 
model was used to test whether mate-
rial in the circulation might alter the aged 
phenotype (Conboy et al., 2005). Comin-
gling the circulatory systems of an aged 
mouse and a young mouse reverted 
impaired muscle stem cell activity in the 
older animal to a younger phenotype. 
The improved phenotype was observed 
in molecular terms (increased Notch sig-
naling) and in repair of muscle injury. Wnt 
regulating factors in serum have been 
implicated in the improved phenotype as 
increased Wnt signaling in aged animals 
favors a fibrotic rather than a myogenic 
response (Brack et al., 2007). These 
studies have clear implications for drug-
based enhancement of stem cell func-
tion and tissue repair.
Patient-Specific Stem Cell Therapies
Like organ transplants, stem cell trans-
plants confront an immune barrier, which 
requires either that transplants be autolo-
gous (derived from “self-tissues”) or that 
patients take immunosuppressive drugs 
if the transplants are allogeneic (that is, 
from unrelated donors). To provide wider 
access to cell therapies and to avoid the 
need for immune suppression, one of the , February 22, 2008 ©2008 Elsevier Inc. 545
ambitions of regenerative medicine is to 
produce genetically equivalent (isogenic) 
cells. This can be achieved by producing 
pluripotent ESCs from adult somatic cells 
by somatic cell nuclear transfer (SCNT; 
in which an adult somatic cell nucleus 
is injected into an enucleated oocyte) 
or by direct reprogramming of the adult 
somatic cells back to a pluripotent state 
using a transcription factor cocktail.
Pluripotent Stem Cells by SCNT
Pluripotent ESCs created by SCNT 
(so-called ntESCs) can be used both 
to model diseases and as rejection-
proof “autologous” tissues for cell 
replacement therapies. This theoretical 
approach has been reduced to practice 
in mouse models to treat genetic immu-
nodeficiency with HSCs (Rideout et al., 
2001) and to treat a Parkinson’s-like 
syndrome with dopaminergic neurons 
(Barberi et al., 2003). Although cloned 
organisms resulting from SCNT have 
health defects due to faulty reprogram-
ming, ntESCs seem to be equivalent to 
ESCs derived from naturally fertilized 
embryos (Brambrink et al., 2006). Appar-
ently the process of establishing ESCs 
in culture entails a winnowing of incom-
pletely reprogrammed clones and selec-
tion for those clones that have sustained 
effective reprogramming and pluripo-
tency. Although ntESCs can be readily 
generated from the mouse, only recently 
have two ntESC lines been derived from 
rhesus macaques (Byrne et al., 2007). 
This report suggests that SCNT might 
indeed be feasible in humans, and as 
long as healthy oocytes are available 
for research, it is only a matter of time 
before cloned human blastocysts and 
human ntESC lines are generated by 
SCNT (French et al., 2008).
Pluripotent Stem Cells by  
Reprogramming
Given the hardships involved in donat-
ing oocytes, alternatives that avoid the 
need for oocytes altogether are ulti-
mately preferable but depend on being 
able to recapitulate the reprogramming 
process in vitro. The groundbreaking 
work of Shinya Yamanaka has shown 
that retroviral transduction of only 
four genes encoding the transcription 
factors c-Myc, Klf4, Oct4, and Sox2 
is sufficient to induce a state of pluri-
potency in adult murine and human 
fibroblasts (Takahashi et al., 2007; 546 Cell 132, February 22, 2008 ©2008 ElseTakahashi and Yamanaka, 2006). This 
work has been corroborated by oth-
ers in the murine (Maherali et al., 2007; 
Wernig et al., 2007) and human (Park 
et al., 2008; Yu et al., 2007) systems. 
The four transcription factors are 
introduced by retroviral infection and 
appear to mediate the reprogramming 
process over several weeks in culture, 
resulting in induced pluripotent (iPS) 
cells that closely resemble ESCs (see 
Review by R. Jaenisch and R. Young in 
this issue). In all cases, the retroviruses 
are silenced, and the pluripotent state 
of the reprogrammed cells ultimately 
hinges upon the activity of endog-
enous genes. Unraveling the mecha-
nisms of reprogramming should iden-
tify ways to make this process more 
efficient. However, there are challenges 
if iPS cells are to be used therapeuti-
cally because three of the reprogram-
ming factors—Myc, Klf4, and Lin28 (or 
close relatives)—have been linked with 
oncogenesis, and although Myc is not 
essential for reprogramming, retroviral 
insertion alone can cause deleterious 
and cancer-causing mutations. Indeed, 
the reversion of mesenchymal cells 
(fibroblasts) to iPS colonies expressing 
cadherins mimics the mesenchymal-
to-epithelial transition characteristic of 
malignant transformation in some tis-
sues, suggesting that reprogramming 
and tumorigenesis may entail a similar 
dedifferentiation process. By repro-
gramming adult somatic cells from 
patients to iPS cells that can then be 
differentiated into a variety of tissues 
in vitro, the goal is to generate patient-
specific tissues for regenerative medi-
cine. An important next step will be 
to evaluate whether methods for tran-
sient expression of the three or four 
factor reprogramming cocktail might 
be sufficient to induce iPS cell forma-
tion, and whether small molecules can 
replace these transcription factors. It is 
appealing to imagine that therapeutic 
reprogramming strategies might ulti-
mately be aimed at diverting one adult 
somatic cell type directly into another, 
without reverting all the way back to a 
pluripotent state.
Single-gene disorders may be the best 
targets for combined gene repair and 
cell replacement therapy using pluripo-
tent stem cells. Such cells are immortal vier Inc.in culture, which facilitates precise gene 
repair and characterization of the cells 
for safety. A recent study demonstrates 
the feasibility of this approach (Hanna et 
al., 2007). These investigators reported 
amelioration of symptoms in a mouse 
model of sickle cell anemia after trans-
plant of HSCs derived from iPS cells 
(prepared from skin cells of these mice) 
in which the genetic defect had been 
repaired. Although promising, both direct 
reprogramming and reprogramming by 
SCNT remain highly cumbersome, labor-
intensive, and inefficient processes and 
present enormous practical barriers to 
their widespread use to treat disease.
Overcoming the Immune Response
We assume that tissue histocompat-
ability is a prerequisite for cell replace-
ment therapy, but there is a remark-
able vacuum of knowledge about the 
immune responses directed against 
most classes of stem cells. Some data 
suggest that human ESCs may be less 
susceptible to immune attack either 
because of low-level expression of class 
I HLA molecules or active suppression 
of the immune response through uncer-
tain mechanisms (Drukker et al., 2006; Li 
et al., 2004). Study of the host immune 
response to transplanted stem cells 
needs to be given more prominence in 
the stem cell field.
Because of the cost and inconve-
nience of customized patient-specific 
therapies, an appealing strategy is to 
engineer a pluripotent cell line that is 
invisible to the immune system and 
can thereby serve as a universal donor. 
Such a cell might have to be rendered 
deficient in class I and II HLA genes 
and ligands that activate cytotoxicity 
receptors on natural killer (NK) cells, to 
express class I mimics such as HLA-G 
(Mandelboim et al., 1997), and to engage 
inhibitory NK cell receptors. Generating 
such a cell is daunting given that it might 
entail genetic manipulation of scores of 
loci. An alternative strategy might be to 
express proteins in transplanted cells 
that would actively antagonize invading 
immune cells. Expression of indoleamine 
dioxygenase, an enzyme that degrades 
tryptophan, an essential amino acid nec-
essary for T cell function, is believed to 
be an important feature of the immune 
privilege of the invading trophoblast tis-
sue of the developing embryo (Munn et 
al., 1998; see Essay by J. Rossant in this 
issue). Indeed, a better understanding of 
the immune mechanisms operating at 
the maternal-fetal interface may help to 
define ways to achieve universal donor 
capability from a single or very limited 
number of human pluripotent cell lines.
Prospects for Stem Cell Banking
International registries of bone marrow 
donors and public cord blood banks 
enable the transplantation of alloge-
neic HSCs to treat a variety of blood 
cancers and genetic diseases, but will 
such registries and banks be required 
for the widespread application of stem 
cell transplants? Interestingly, computer 
simulations that match individuals in 
transplant donor registries with potential 
recipients have shown that a large but 
feasible number of carefully selected cell 
lines could be banked and could provide 
a productive tissue match for large seg-
ments of the population (if we accept the 
need for immunosuppressive medica-
tion). In a study to identify histocompat-
ibility between 10,000 potential donors 
and some 6500 renal allograft recipi-
ents, only 150 donors were needed to 
identify a perfect 6/6 antigen match for 
nearly 20% of the recipients; when the 
criteria were loosened to allow a single 
antigen match only, the same number of 
donors matched nearly 85% of recipi-
ents (Taylor et al., 2005). Importantly, 
donors with homozygosity, which pres-
ent only 3 rather than 6 distinct histo-
compatiblity antigens, were far more 
likely to yield productive matches with 
recipients. Indeed, as few as 10 donors 
produced perfect matches for nearly 
38% of recipients and productive single 
antigen matches for 67% of recipients. A 
simulation performed within a Japanese 
cohort concluded that 100 homozygous 
donors could match 80% of the recipi-
ents (Nakajima et al., 2007). Both of 
these studies highlight the feasibility of 
creating banks of stem cell lines for tis-
sue transplantation.
Humans with homozygous HLA hap-
lotypes are rare in the population but 
might be identified from transplant reg-
istries and approached to donate tissue 
for generating pluripotent stem cells. 
Alternatively, pluripotent stem cells with 
homozygous HLA might be generated from parthenogenetic embryos (pESCs; 
Kim et al., 2007a; Revazova et al., 2007). 
Primate pESCs have been derived from 
cynomolgous monkeys (Cibelli et al., 
2002), and the first human ESC line pur-
portedly made by SCNT has actually 
proven to be the first human pESC line 
(Kim et al., 2007b). Recently, an indepen-
dent group has confirmed the isolation 
of 10 human pESCs at robust efficiency, 
including 4 that show HLA homozygos-
ity (Revazova et al., 2007). Generating 
pESCs from even modest numbers of 
human oocytes appears practical and 
could be the basis for building banks of 
stem cells that could provide a source of 
tissues for transplantation. Because of 
aberrant imprinting, tissues from pESCs 
might not grow or function properly, but 
stable and functional hematopoietic 
engraftment has been reported from 
parthenogenetic cells in mice (Eckardt 
et al., 2007) and in a rare human parthe-
nogenetic chimera (Strain et al., 1995). 
If pESC-derived tissues prove safe and 
effective after careful functional analy-
ses, then pESCs might represent a 
favorable resource for stem cell banking 
and “off-the-shelf” tissue replacement 
therapies.
Unanticipated challenges in safety or 
efficacy might render stem cells or their 
progeny less than ideal for cell replace-
ment therapies. Nevertheless, insights 
gleaned from stem cell biology may facil-
itate classical drug development and will 
no doubt accelerate progress in affiliated 
fields like tissue engineering, physiology, 
systems biology, and developmental 
biology. Even in the unlikely case that 
stem cells fail to realize their promise for 
tissue replacement therapy, their value 
for in vitro discovery will forever remain 
unchallenged.
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